Recent research have centered on the convergence of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|GCGR agonist therapies and DA neurotransmission. While GIP activators are increasingly employed for managing type 2 diabetes, their unexpected consequences on reward circuits, specifically influenced by dopamine networks, are … Read More